Daily Cardiology Research Analysis
Analyzed 235 papers and selected 3 impactful papers.
Summary
Three high-impact cardiology studies stand out today: US real-world registry data confirm the safety and effectiveness of transcatheter tricuspid valve replacement (TTVR) with robust early clinical and health-status gains; progression of device-detected subclinical atrial fibrillation strongly predicts heart failure hospitalization or death; and in 60–75-year-olds, transfemoral TAVR shows lower in-hospital mortality than surgery and is trending toward greater cost-effectiveness.
Research Themes
- Structural heart interventions and real-world outcomes
- Atrial arrhythmia progression and heart failure risk
- Comparative effectiveness and cost-effectiveness in valve therapies
Selected Articles
1. Real-World Outcomes of Transcatheter Tricuspid Valve Replacement: Analysis From the STS/ACC TVT Registry.
In a US registry of 1,034 attempted TTVR procedures, implantation succeeded in 98.4%, with mild-or-less TR in 98% immediately and 97.7% at 30 days. Thirty-day mortality was 3.1%, stroke 0.2%, bleeding 7.9%, and KCCQ improved by 22.4 points, mirroring pivotal trial performance in an older, comorbid population.
Impact: This is the first large-scale, post-approval real-world evaluation of TTVR showing consistent safety, near-complete TR reduction, and meaningful health-status gains.
Clinical Implications: Heart teams can confidently adopt TTVR for severe TR with expectations of high procedural success, near-complete TR elimination, and rapid symptom and quality-of-life improvement; plan for potential new CIED implantation and bleeding mitigation.
Key Findings
- Implant success 98.4% across 82 US centers; mild-or-less TR in 98.4% post-procedure and 97.7% at 30 days.
- Thirty-day outcomes: all-cause mortality 3.1%, stroke 0.2%, bleeding 7.9%, heart failure hospitalization 3.1%.
- NYHA class improved to I/II in 82.7%; KCCQ-OS improved by 22.4 points from baseline to 30 days.
- Baseline CIED status did not affect 30-day mortality, HF hospitalization, or functional outcomes.
- Rates of new CIED implantation were 15.9% in CIED-naive patients; bleeding and CIED rates were lower than in RCTs.
Methodological Strengths
- Large, national, real-world registry with consecutive enrollment
- Standardized outcome capture including health status (KCCQ) and echocardiography
Limitations
- Retrospective observational design with potential selection bias and unmeasured confounding
- Short 30-day follow-up without longer-term durability or comparative control group
Future Directions: Establish 1- and 2-year durability, right ventricular remodeling, and survival; identify predictors of new CIED requirement; head-to-head comparisons with transcatheter edge-to-edge repair in defined anatomies.
IMPORTANCE: Transcatheter tricuspid valve replacement (TTVR) demonstrated superior outcomes over medical therapy in patients with severe tricuspid regurgitation (TR) in the Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy Using a Novel Device II (TRISCEND II) randomized clinical trial, and received regulatory approval in the US in 2024. Contemporary real-world data on its effectiveness and safety remain limited. OBJECTIVE: To evaluate 30-day clinical, echocardiographic, and health status outcomes of TTVR in real-world use. DESIGN, SETTING, AND POPULATION: Retrospective cohort study of all consecutive patients who underwent TTVR in the US from February 2024 through March 2025 in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Patients had symptomatic, severe TR despite optimal medical therapy and TTVR was deemed appropriate by a heart team. Statistical analysis was conducted from September 2025 to February 2026. EXPOSURE: Device-enabled TTVR. MAIN OUTCOMES AND MEASURES: Thirty-day event rates (all-cause death, stroke, bleeding, new cardiac implantable electronic device [CIED] implantation, heart failure hospitalizations), TR reduction, and changes in health status (New York Heart Association [NYHA] functional class and Kansas City Cardiomyopathy Questionnaire Overall Summary [KCCQ-OS] score) are reported. Subgroup analyses examined the impact of baseline CIED status on outcomes. RESULTS: Among 1034 attempted procedures at 82 centers (mean [SD] age, 77.1 [10.6] years; 69.1% female; 73.2% NYHA functional class III/IV), a valve was successfully implanted in 1017 patients (98.4%). Mild or less TR was achieved in 98.4% of patients post procedure and in 97.7% at 30 days. At 30 days, all-cause mortality was 3.1%; stroke, 0.2%; bleeding, 7.9%; new CIED, 15.9% in CIED-naive patients; and heart failure hospitalization, 3.1%. There were significant improvements in NYHA functional class (class I/II, 82.7%; P < .001) and mean KCCQ-OS score (22.4 points; P < .001) from baseline to 30 days. There were no significant differences in 30-day mortality (P = .47), heart failure hospitalization (P > .99), and functional outcomes (P = .55) when patients were stratified by baseline CIED status. CONCLUSIONS AND RELEVANCE: Early US real-world experience with TTVR confirms safety and effectiveness in patients with severe TR. Thirty-day outcomes are consistent with the TRISCEND II pivotal trial, demonstrating acceptable safety, near-complete TR elimination, and significant health status improvements in an older, comorbid population. Rates of new CIED implantation and bleeding were lower than randomized clinical trial experience.
2. Subclinical atrial fibrillation and the risk of heart failure: insights from ARTESiA.
In 3,986 ARTESiA participants with device-detected SCAF, 31% progressed to >24 h SCAF or clinical AF over 4.1 years. Heart failure hospitalization or death occurred in 13%, and SCAF progression independently increased risk (HR 2.72), whereas episodes <24 h were not associated with HF events.
Impact: This large, adjudicated analysis delineates which SCAF phenotypes drive HF events, reframing surveillance and management toward progression rather than short episodes.
Clinical Implications: Prioritize longitudinal monitoring to detect SCAF progression and consider early rhythm management and HF risk mitigation when episodes extend beyond 24 h or transition to clinical AF.
Key Findings
- Among 3,986 patients with SCAF, 31% progressed to >24 h SCAF or clinical AF over 4.1 years.
- HF hospitalization or HF-related death occurred in 13% (3.3 per 100 person-years).
- SCAF progression independently predicted HF hospitalization or death (HR 2.72, 95% CI 2.24–3.31).
- Baseline SCAF episodes <24 h were not associated with HF events.
- Findings support surveillance strategies that emphasize detection of episode prolongation/clinical AF.
Methodological Strengths
- Large sample with adjudicated outcomes from a randomized trial framework
- Time-dependent modeling of SCAF progression to capture dynamic risk
Limitations
- Secondary analysis; treatment allocation (apixaban vs aspirin) not the focus of this analysis
- Device-detection parameters and management strategies may vary; residual confounding possible
Future Directions: Prospective strategies to prevent SCAF progression and HF events (e.g., rhythm control, upstream therapy) and integration of device analytics to refine individualized surveillance.
AIMS: Heart failure (HF) and clinical atrial fibrillation are closely linked, but the relationship between device-detected subclinical atrial fibrillation (SCAF) and HF is unclear. We aimed to determine incidence and clinical risk factors for HF events among patients with SCAF. METHODS: We included 3986 patients from the ARTESiA (Apixaban for the Reduction of Thromboembolism in Patients with Device-Detected Subclinical Atrial Fibrillation) trial. ARTESiA investigated the effect of apixaban versus aspirin for stroke prevention in patients with episodes of SCAF ≤24 hours. In this secondary analysis, we explored the number and duration of SCAF episodes at baseline as risk markers for HF hospitalization or HF-related death. SCAF progression was analysed as a time-dependent covariate and defined as the development of SCAF >24 hours or clinical atrial fibrillation. RESULTS: Over a mean follow-up of 4.1 ± 1.7 years, SCAF progression was observed in 1244 patients (31%). Heart failure hospitalization or HF-related death occurred in 515 (13%) patients at a rate of 3.3 [95% confidence interval (CI) 3.1-3.6] per 100 person-years. A total of 172 HF-related events occurred after SCAF progression (7.2 events, 95% CI 6.2-8.3, per 100 PY). SCAF progression was an independent risk factor for HF hospitalization or HF-related death (hazard ratio 2.72, 95% CI 2.24-3.31). CONCLUSION: Heart failure hospitalization and HF-related death are common in patients with SCAF. Progression to longer SCAF episodes or clinical AF were associated with HF events, but episodes <24 h were not. These findings underscore the need for close surveillance of SCAF patients to detect complications and potentially improve outcomes.
3. In-hospital outcomes and cost-effectiveness of transcatheter aortic valve replacement among younger patients: a double/debiased machine learning approach using electronic health records in Germany.
In 28,805 German EHR patients aged 60–75, transfemoral TAVR reduced in-hospital mortality (RR 0.65) and key complications versus SAVR using debiased ML. Although reimbursement per case was higher for TAVR, the cost gap narrowed over time and 1-year ICERs suggest improving cost-effectiveness.
Impact: This large causal-inference analysis directly informs treatment selection and policy for younger severe AS patients by jointly addressing outcomes and evolving costs.
Clinical Implications: For selected 60–75-year-olds, TF-TAVR offers lower in-hospital mortality and complications than SAVR and is trending toward favorable cost-effectiveness, supporting broader consideration with individualized decision-making.
Key Findings
- TF-TAVR reduced in-hospital mortality vs SAVR (causal RR 0.65; p=0.012).
- Lower bleeding (RR 0.29), postoperative delirium (RR 0.32), and prolonged ventilation >48 h (RR 0.39) with TF-TAVR.
- No significant difference in acute kidney injury (RR 0.89; p=0.150).
- Higher reimbursement for TF-TAVR (€7,071 more/case), but a 12% decrease over 2018–2022 narrowed the gap.
- ICERs: €857,413 (in-hospital), €196,422 (1-year), indicating improving cost-effectiveness over time.
Methodological Strengths
- Very large national EHR cohort with contemporary practice (2018–2022)
- Double/debiased machine learning for robust causal estimates and integrated cost-effectiveness analysis
Limitations
- Observational design; reimbursement used as a proxy for costs and may not capture all resource use
- ICERs modeled without lifetime horizon; unmeasured confounding possible despite debiased methods
Future Directions: Prospective comparative effectiveness with longer horizons, granular cost data, and patient-reported outcomes; subgroup analyses by anatomy and frailty to refine selection.
BACKGROUND: The prevalence of severe symptomatic aortic stenosis is increasing with population aging. Although surgical aortic valve replacement (SAVR) has traditionally been the standard treatment, transfemoral transcatheter aortic valve replacement (TF-TAVR) is increasingly used. The optimal treatment for patients aged 60-75 remains debated. METHODS: This retrospective cohort study analyzed 28,805 German patients who underwent isolated SAVR or TF-TAVR (2018-2022). We applied double/debiased machine learning estimators that combined adaptive lasso variable selection with propensity score-based weighting across 21 baseline characteristics. Cost-effectiveness was assessed via incremental cost-effectiveness ratios (ICER) and cost-effectiveness acceptability curves from in-hospital and 1-year perspectives. RESULTS: Compared with SAVR, TF-TAVR was associated with a significant reduction in in-hospital mortality (causal risk ratio [RR] 0.65; p = 0.012), along with lower rates of bleeding (RR 0.29; p < 0.001), postoperative delirium (RR 0.32; p < 0.001), and mechanical ventilation > 48 h (RR 0.39; p < 0.001). No significant difference was observed in acute kidney injury rates (RR 0.89; p = 0.150). However, reimbursement was substantially higher for TF-TAVR (€7071 more per case, p < 0.001). A hypothetical shift from SAVR to TF-TAVR was associated with an ICER of €857,413 (95% CI €472,195-€4,310,651) from the in-hospital perspective and €196,422 (95% CI €123,873-€457,813) from the 1-year perspective. Notably, unadjusted analyses indicated a narrowing cost gap over time: Reimbursement for TF-TAVR decreased by approximately 12% between 2018 and 2022, while SAVR costs remained stable. Consequently, TF-TAVR is becoming increasingly cost-effective. CONCLUSION: Given an estimated life expectancy of 11 to 25 years in this population, the incremental costs per life saved associated with a hypothetical shift from SAVR to TF-TAVR appear justifiable. Nonetheless, individual patient circumstances must always be considered in decision-making.